#United States #New York #Pomerantz LLP #ADC Therapeutics #ZYNLONTA

Investor Alert: Pomerantz LLP Investigates ADC Therapeutics

Pomerantz LLP, a distinguished law firm known for its expertise in corporate, securities, and antitrust class action litigation, has initiated an investigation into ADC Therapeutics SA (NYSE: ADCT) on behalf of its investors. This probe comes in response to recent developments regarding the company's clinical trial outcomes and potential allegations of securities fraud.

Background of the Investigation

On December 3, 2025, ADC Therapeutics made headlines with the announcement of updated results from the LOTIS-7 Phase 1b open-label clinical trial. This clinical trial was primarily designed to evaluate the safety and efficacy of ZYNLONTA® in combination with glofitamab (COLUMVI®) for patients suffering from relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the announcement conveyed a positive outlook on the preliminary results, it also indicated that adverse events were reported in two patients, raising concerns regarding the treatment's safety.

Moreover, the firm disclosed that cytokine release syndrome of various grades affected 36.7% of patients across different dosages, which could have implications on the overall perception of its treatment options. Following the release of this information, ADC Therapeutics saw a significant drop in its stock price, diminishing by $0.65 per share, or 14.13%, culminating in a closing price of $3.95 per share on the same day.

Legal Implications and Next Steps

The critical nature of these findings has prompted Pomerantz LLP to seek contact from investors who might have been adversely affected by ADC's disclosure. Investors are encouraged to reach out to Danielle Peyton at the firm for further information regarding the potential class action lawsuit. The investigation aims to determine if company officers or directors engaged in any wrongful activities that could have led to misrepresentation or misstatements affecting investors' decisions.

As a firm recognized for safeguarding the rights of investors, Pomerantz has a long-standing history of handling complex securities litigation. Founded over 85 years ago by Abraham L. Pomerantz, the firm continues to represent victims of corporate misconduct fiercely. Their reputation is built on successful recoveries in multimillion-dollar damages cases for class members.

Importance for Investors

For investors holding stakes in ADC Therapeutics or considering investing in it, this investigation is a significant development. Uncovering the truth behind these allegations is crucial, as outcomes could affect stock prices, investment portfolios, and strategies moving forward. It raises critical questions about the company's operational integrity, regulatory compliance, and investor transparency.

Closing Thoughts

With the increasing scrutiny of corporate behavior and governance, investors must remain vigilant. Investigations like the one launched by Pomerantz LLP not only aim to pursue justice for affected stakeholders but also reinforce the importance of ethical practices in the corporate sector. This ongoing situation serves as a potent reminder of the volatile nature of the biopharmaceutical sector and the potential risks involved in investing within it. As further developments unfold, maintaining an informed position will be essential for all investors regarding ADC Therapeutics.

For those interested in participating in the class action or needing more detailed insights into their legal rights as impacted investors, reaching out to legal experts like Pomerantz LLP may provide the necessary support and guidance needed during this tumultuous period.